BIOKAD, AO

🇷🇺Russia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria

First Posted Date
2019-08-19
Last Posted Date
2021-02-12
Lead Sponsor
Biocad
Target Recruit Count
28
Registration Number
NCT04060264
Locations
🇷🇺

Federal State Budgetary Educational Institution of Higher Education "Academician I.P. Pavlov First St. Petersburg State Medical University" of the Ministry of Healthcare of Russian Federation, Saint Petersburg, Russian Federation

Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

First Posted Date
2019-08-14
Last Posted Date
2021-09-08
Lead Sponsor
Biocad
Target Recruit Count
270
Registration Number
NCT04056897
Locations
🇷🇺

State Budgetary Healthcare Institution of Nizhny Novgorod region "Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod", Nizhny Novgorod, Russian Federation

Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®

Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-07-22
Last Posted Date
2020-05-15
Lead Sponsor
Biocad
Target Recruit Count
78
Registration Number
NCT04027803
Locations
🇷🇺

Limited Liability Company Research Center Eco-Bezopasnost (OOO Research Center Eco-Bezopasnost), Saint Petersburg, Russian Federation

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

First Posted Date
2019-04-12
Last Posted Date
2023-02-10
Lead Sponsor
Biocad
Target Recruit Count
117
Registration Number
NCT03913923
Locations
🇧🇾

State Institution "N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology", The Settlement Of Lesnoy, Minsk District, Belarus

🇧🇾

Healthcare Institution "Minsk Municipal Clinical Oncolo-gy Dispensary" (MMCOD), Minsk, Belarus

🇷🇺

Clinical Oncologic Dispensary No. 2, Sochi, Krasnodar Territory, Russian Federation

and more 20 locations

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

First Posted Date
2019-04-11
Last Posted Date
2020-09-17
Lead Sponsor
Biocad
Target Recruit Count
292
Registration Number
NCT03912389
Locations
🇨🇿

Regional Hospital Liberec, Liberec, Czechia

🇨🇿

University Hospital Olomouc, Olomouc, Czechia

🇨🇿

University Hospital Ostrava, Ostrava, Czechia

and more 34 locations

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

First Posted Date
2019-04-11
Last Posted Date
2019-05-09
Lead Sponsor
Biocad
Target Recruit Count
49
Registration Number
NCT03912402
Locations
🇷🇺

Stavropol Regional Clinical Oncology Center, Stavropol', Stavropol Krai, Russian Federation

🇷🇺

Republican Clinical Oncology Cente, Kazan, Republic Of Tatarstan, Russian Federation

🇷🇺

City Hospital No. 5, Barnaul, Altai Krai, Russian Federation

and more 21 locations

First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-04-11
Last Posted Date
2020-09-18
Lead Sponsor
Biocad
Target Recruit Count
15
Registration Number
NCT03912441
Locations
🇷🇺

Medical Center "Eco-Safety", Saint Petersburg, Russian Federation

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)

First Posted Date
2019-04-11
Last Posted Date
2020-09-18
Lead Sponsor
Biocad
Target Recruit Count
316
Registration Number
NCT03912415
Locations
🇬🇪

LEPL First University Clinic of Tbilisi State Medical University, Tbilisi, Georgia

🇷🇺

Sverdlovsk Regional Oncology Center, Ekaterinburg, Russian Federation

🇷🇺

State Health Care Institution "Moscow City Oncology Hospital № 62" Moscow Health Department, Moscow, Russian Federation

and more 23 locations

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-10-03
Last Posted Date
2020-04-21
Lead Sponsor
Biocad
Target Recruit Count
57
Registration Number
NCT03693950
Locations
🇷🇺

BIOCAD, Saint Petersburg, Strelna, Russian Federation

Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis

Phase 3
Conditions
Interventions
First Posted Date
2018-07-26
Last Posted Date
2021-09-08
Lead Sponsor
Biocad
Target Recruit Count
194
Registration Number
NCT03598751
Locations
🇧🇾

1st City Clinical Hospital, Minsk, Belarus

🇷🇺

North-Western State Medical University n.a. I.I.Mechnikov, Saint-Petersburg, Russian Federation

🇷🇺

Chelyabinsk Regional Clinical hospital, Chelyabinsk, Russian Federation

© Copyright 2024. All Rights Reserved by MedPath